Journals / Fırat Tıp Dergisi / 2015 / Cilt: 20 - Sayı: 2

The Affects of Adriamycin Implementation to The Immunreactivity of Nesfatin-1 at Rat Heart Tissue

Adriamisin Uygulamasının Sıçan Kalp Dokusunda Nesfatin-1 İmmünreaktivitesi Üzerine Etkileri

Pages
81–85
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: As a result, rat heart tissue releases nesfatin-1, experimental implementation of adriamycin reduces nesfatin-1 immunoreactivity in rat heart tissue, and this decrease depends on myocardial damage / loss due to adriamycin.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Adriamycin is a broad-spectrum anticancer drug that is used at various type of solid tumors and hematologic malignancies.
📊
Key Findings & Data:Nesfatin-1 is closely associated with diabetes, obesity, anorexia nervosa, psychiatric disorders, and neurogenic diseases.
💡
Conclusion & Impact:Conclusion: As a result, rat heart tissue releases nesfatin-1, experimental implementation of adriamycin reduces nesfatin-1 immunoreactivity in rat heart tissue, and this decrease depends on myocardial damage / loss due to adriamycin.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Adriamycin is a broad-spectrum anticancer drug that is used at various type of solid tumors and hematologic malignancies. The main side effects of adriamycin are heart failure and cardiomyopathy. Studies suggests that, oxidative stress plays an important role in the pathogenesis of adriamycin cardiotoxicity. Nesfatin-1 is closely associated with diabetes, obesity, anorexia nervosa, psychiatric disorders, and neurogenic diseases. It has been reported that Nesfatin -1 directly affects the myocardial performance and protects the myocardium from ischemia reperfusion injury. Material and Method In this study Wistar albino rats were used. Rats were divided into 2 groups. No application was made to control group at 14 days. To adriamycin group, 10mg/kg single dose adriamycin was injected intraperitoneally. Finally rats were decapitated and heart tissues were removed. With routine procedures, tissues were embedded in paraphine blockes. For nesfatin-1 immunreactivity ‘‘avidin-biotin-peroxidase’’ method was applied. Results In control group was observed at +3 diffusiveness in myocytes at heart tissue. In comparison with control group, nesfatin-1 immunoreactivity showed significant decrease at adriamycin group and was at +1 diffusiveness. Conclusion: As a result, rat heart tissue releases nesfatin-1, experimental implementation of adriamycin reduces nesfatin-1 immunoreactivity in rat heart tissue, and this decrease depends on myocardial damage / loss due to adriamycin.

Özet

Amaç: Adriamisin birçok solid tümörün ve hematolojik malignitenin tedavisinde kullanılan geniş spektrumlu bir kanser ilacıdır. Adriamisin kullanımının ana yan etkisinin kalp yetmezliği ve kardiyomyopati olduğu bilinmektedir. Yapılan çalışmalar adriamisin kardiyotoksisitesinin patogenezinde oksidatif stresin önemli bir rol oynadığını göstermektedir. Nesfatin-1 diyabet, obezite, anoreksia nervoza, psikiyatrik bozukluklar ve nörojenik hastalıklar ile yakından ilişki göstermektedir. Nesfatin-1’in miyokardiyal performansı direk olarak etkilediği ve kalp kasını iskemi reperfüzyon hasarından koruduğu bildirilmiştir. Gereç ve Yöntem: Çalışmamızda erişkin Wistar albino erkek sıçanlar kullanıldı. Deney hayvanları her grupta 6 hayvan olmak üzere 2 gruba ayrıldı. Kontrol grubuna deney süresi olan 14 gün boyunca herhangi bir işlem yapılmadı. Adriamisin grubuna ise10 mg/kg/tek doz adriamisin intraperitoneal olarak verildi. Deney sonunda sıçanlar anestezi altında dekapite edilerek kalp dokuları çıkarıldı. Rutin protokoller ile dokular parafin bloklara gömüldü. Kesitlere Nesfatin-1 immünreaktivitesi için avidin-biotin-peroksidaz yöntemi uygulandı. Sitoplazmik immün boyanmanın yaygınlığı 0’dan +3’e kadar sayı ile semi-kantitatif olarak skorlandı. Bulgular: Nesfatin-1 immünreaktivitesi, kontrol grubunda kalp dokusunda miyositlerde +3 yaygınlığında izlendi. Kontrol grubu ile karşılaştırıldığında nesfatin-1 immünreaktivitesinde adriamisin grubunda miyositlerde belirgin bir azalma vardı ve +1 yaygınlığında tespit edildi. Sonuç: Sıçan kalp dokusunda nesfatin-1 salınımın olduğu, deneysel adriamisin uygulanmasının sıçan kalp dokusunda nesaftin-1 immünreaktivitesini azalttığı, bunun da adriamisine bağlı miyosit hasarı ve/veya kaybına bağlı olabileceği kanaatindeyiz.

🔖

Cite This Article

KULOĞLU, T., ARTAŞ, G. (2015). The Affects of Adriamycin Implementation to The Immunreactivity of Nesfatin-1 at Rat Heart Tissue. Fırat Tıp Dergisi, Cilt: 20 - Sayı: 2, 81–85. https://ajindex.com/articles/196577

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Cui J, Li C, Guo W, et al. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy. J Control Release 2007; 118: 204-15.
  2. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 1996; 98: 1253-60.
  3. Quiles JL, Huertas JR, Battino M, Mataix J, Ramırez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002; 180: 79-95.
  4. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691–743. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracy-clines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
  5. Wang G, Zhang J, Liu L, Sharma S, Dong Q. Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS ONE 2012; 7: 5176. Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 2001; 3: 135-45. 8. 9. 10. 11. 12. 13. 14. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity, analysis of prevailing hypothesis. FASEB J 1990; 4: 3076-86.
  6. Rabelo E, DE Angelis K, Bock P, et al. Baroreflex sensitivity and oxidative stres in adriamycin induced heart failure. Hypertension 2001; 38: 576-80.
  7. Zhang YW, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009; 57: 435-45.
  8. Mantawy EM, El-Bakly WM, Esmat A, Badr AM, El- Demerdash E. Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Eur J Pharmacol 2014; 728: 107- 18. Dai H, Li X, He T, et al. Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction. Peptides 2013; 46: 167-71.
  9. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709-12.
  10. Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun 2010; 391: 1039-42. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. Elmquist JK, Coppari R, Balthasar N, Ichinose M, Lowell BB. Identifying hypothalamic pathways controlling food intake, body weight, and glucose